Indiana House Bill HB1571 Introduced / Bill

                     
Introduced Version
HOUSE BILL No. 1571
_____
DIGEST OF INTRODUCED BILL
Citations Affected: IC 16-18-2-298.5; IC 16-19-4-11; IC 16-42-19;
IC 25-26; IC 27-1-24.5; IC 27-2-9.5; IC 34-30-2.1; IC 35-48-1-24.
Synopsis:  Pharmacists. Removes the authority of the state health
commissioner's designated public health authority to issue a standing
order, prescription, or protocol (standing order) to allow certain health
practitioners to administer or dispense an immunization or a pharmacist
a smoking cessation product. Requires the state health commissioner
to issue a standing order that allows a pharmacist to treat or screen,
test, administer, or dispense for certain health conditions. Requires the
Indiana board of pharmacy to establish standards and requirements for
courses of education concerning Indiana and federal statutes and rules
governing the practice of pharmacy. Requires an individual to pass the
North American Pharmacist Licensure Examination to be eligible for
licensure as a pharmacist. Allows a pharmacist to administer or
dispense an immunization that is recommended by the federal Centers
for Disease Control and Prevention Advisory Committee on
Immunization Practices under a drug order, under a prescription, or
according to a protocol approved by a physician. Removes provisions
restricting a pharmacist from administering an immunization to an
individual who is less than 11 years of age. Provides civil and criminal
immunity for a pharmacist related to filling a prescription for a drug,
medicine, or other prescribed substance. Allows a pharmacist to take
certain actions relating to medication assisted treatment. Sets forth
requirements for pharmacy benefit managers. Establishes requirements
for a health carrier regarding the reimbursement of services and
procedures that are performed by a pharmacist. 
Effective:  July 1, 2025.
Goss-Reaves
January 21, 2025, read first time and referred to Committee on Public Health.
2025	IN 1571—LS 7666/DI 141 Introduced
First Regular Session of the 124th General Assembly (2025)
PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana
Constitution) is being amended, the text of the existing provision will appear in this style type,
additions will appear in this style type, and deletions will appear in this style type.
  Additions: Whenever a new statutory provision is being enacted (or a new constitutional
provision adopted), the text of the new provision will appear in  this  style  type. Also, the
word NEW will appear in that style type in the introductory clause of each SECTION that adds
a new provision to the Indiana Code or the Indiana Constitution.
  Conflict reconciliation: Text in a statute in this style type or this style type reconciles conflicts
between statutes enacted by the 2024 Regular Session of the General Assembly.
HOUSE BILL No. 1571
A BILL FOR AN ACT to amend the Indiana Code concerning
professions and occupations.
Be it enacted by the General Assembly of the State of Indiana:
1 SECTION 1. IC 16-18-2-298.5, AS AMENDED BY P.L.96-2017,
2 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3 JULY 1, 2025]: Sec. 298.5. (a) "Public health authority", for purposes
4 of IC 16-22-8 and IC 16-41-9, means:
5 (1) the state health commissioner of the state department;
6 (2) a deputy or an assistant state health commissioner appointed
7 by the state health commissioner, or an agent expressly authorized
8 by the state health commissioner;
9 (3) the local health officer; or
10 (4) a health and hospital corporation established under
11 IC 16-22-8-6.
12 (b) "Public health authority", for purposes of IC 16-19 and
13 IC 16-42-27, means any of the following who is a licensed prescriber:
14 (1) A deputy or assistant state health commissioner appointed by
15 the state health commissioner to act as a public health authority.
16 (2) An agent employed by the state department that is expressly
17 authorized by the state health commissioner to act as a public
2025	IN 1571—LS 7666/DI 141 2
1 health authority.
2 SECTION 2. IC 16-19-4-11, AS AMENDED BY P.L.1-2022,
3 SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
4 JULY 1, 2025]: Sec. 11. (a) The state health commissioner or the
5 commissioner's designated public health authority who is a licensed
6 prescriber may, as part of the individual's commissioner's official
7 capacity, issue a standing order, prescription, or protocol that allows a
8 pharmacist to administer or dispense any of the following:
9 (1) An immunization that is recommended by the federal Centers
10 for Disease Control and Prevention Advisory Committee on
11 Immunization Practices for individuals. who are not less than
12 eleven (11) years of age.
13 (2) A smoking cessation product. However, the pharmacist must
14 inform the patient that the patient must have a follow-up
15 consultation with the patient's licensed prescriber.
16 (b) This subsection does not apply to a pharmacist. The state health
17 commissioner or the commissioner's designated public health authority
18 who is a licensed prescriber may, as part of the individual's
19 commissioner's official capacity, issue a standing order, prescription,
20 or protocol that allows an individual who is licensed, certified, or
21 registered by a board (as defined in IC 25-1-9-1), and if within the
22 individual's scope of practice, to administer or dispense an
23 immunization that is recommended by the federal Centers for Disease
24 Control and Prevention Advisory Committee on Immunization
25 Practices for individuals who are not less than eleven (11) years of age.
26 (c) A standing order described in subsection (a), (b), or (e), or (f)
27 must include the following:
28 (1) The purpose of the order.
29 (2) The eligible recipients.
30 (3) The geographic area covered by the standing order.
31 (4) The procedure for administering or dispensing the
32 immunization or product.
33 (5) A timeline for renewing or updating the standing order.
34 (d) The state health commissioner or designated public health
35 authority who issues a standing order, prescription, or protocol under
36 subsection (a), (b), or (e), or (f) is immune from civil liability related
37 to the issuing of the standing order, prescription, or protocol.
38 (e) Notwithstanding subsection (a) and subsection (b), the state
39 health commissioner or the commissioner's designated public health
40 authority may issue a standing order, prescription, or protocol to
41 administer or dispense an immunization that is recommended by the
42 federal Centers for Disease Control and Prevention Advisory
2025	IN 1571—LS 7666/DI 141 3
1 Committee on Immunization Practices for individuals who are at least
2 five (5) years of age. Nothing in this subsection authorizes the state
3 health commissioner or the commissioner's designated public health
4 authority to:
5 (1) require an individual to receive an immunization for
6 COVID-19; or
7 (2) waive or otherwise allow a minor to receive an immunization
8 without the consent of the parent or guardian as required under
9 IC 16-36-1.
10 This subsection expires at the conclusion of the federal public health
11 emergency concerning COVID-19 that was renewed on October 15,
12 2021, or any subsequent renewal of the declared federal public health
13 emergency concerning COVID-19.
14 (f) The state health commissioner shall, as part of the
15 commissioner's official capacity, issue a standing order,
16 prescription, or protocol that allows a pharmacist to treat or
17 screen, test, administer, or dispense for any of the following:
18 (1) Respiratory illness, including:
19 (A) influenza;
20 (B) severe acute respiratory syndrome coronavirus
21 (SARS-CoV-2); and
22 (C) respiratory syncytial virus (RSV).
23 (2) Group A streptococcus pharyngitis (strep throat).
24 (3) Lice.
25 (4) Emerging or existing public health threats identified by
26 the state health commissioner.
27 SECTION 3. IC 16-42-19-3 IS AMENDED TO READ AS
28 FOLLOWS [EFFECTIVE JULY 1, 2025]: Sec. 3. As used in this
29 chapter, "drug order" means an order that meets the following
30 conditions:
31 (1) Is:
32 (A) a written order in a hospital or other health care institution
33 for an ultimate user for a drug or device, issued and signed by
34 a practitioner; or
35 (B) an order transmitted by other means of communication
36 from a practitioner that is immediately reduced to writing by
37 the pharmacist, registered nurse, or other licensed health care
38 practitioner authorized by the hospital or institution.
39 (2) Is valid until discontinued by the prescriber.
40 (2) (3) Contains the following:
41 (A) The name and bed number of the patient.
42 (B) The name and strength or size of the drug or device.
2025	IN 1571—LS 7666/DI 141 4
1 (C) Unless specified by individual institutional policy or
2 guidelines, the amount to be dispensed either in quantity or
3 days.
4 (D) Adequate directions for the proper use of the drug or
5 device when administered to the patient.
6 (E) The name of the prescriber.
7 SECTION 4. IC 16-42-19-5, AS AMENDED BY P.L.129-2018,
8 SECTION 17, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
9 JULY 1, 2025]: Sec. 5. As used in this chapter, "practitioner" means
10 any of the following:
11 (1) A physician licensed under IC 25-22.5.
12 (2) A veterinarian licensed to practice veterinary medicine in
13 Indiana.
14 (3) A dentist licensed to practice dentistry in Indiana.
15 (4) A podiatrist licensed to practice podiatric medicine in Indiana.
16 (5) An optometrist who is:
17 (A) licensed to practice optometry in Indiana; and
18 (B) certified under IC 25-24-3.
19 (6) An advanced practice registered nurse who meets the
20 requirements of IC 25-23-1-19.5.
21 (7) A physician assistant licensed under IC 25-27.5 who is
22 delegated prescriptive authority under IC 25-27.5-5-6.
23 (8) A pharmacist licensed under IC 25-26.
24 SECTION 5. IC 25-26-13-9, AS AMENDED BY P.L.98-2006,
25 SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
26 JULY 1, 2025]: Sec. 9. (a) The board shall establish standards for
27 pharmacist intern programs. Such standards shall include, but not be
28 limited to, the number of hours students must spend in a program, the
29 number of hours a student must spend in a pharmacy each week, and
30 the types of duties the student may perform.
31 (b) The board shall, by regulation, establish standards and
32 requirements for continuing education and shall endorse those
33 continuing education programs which meet the standards and
34 requirements.
35 (c) The board shall, by regulation, establish standards and
36 requirements for a course of education concerning Indiana statutes
37 and rules governing the practice of pharmacy to be completed by
38 individuals seeking licensure under sections 11(a)(6), 11(c)(3),
39 12(a)(3), and 12(b)(3) of this chapter.
40 (d) The board shall, by regulation, establish standards and
41 requirements for a course of education concerning federal statutes
42 and rules governing the practice of pharmacy to be completed by
2025	IN 1571—LS 7666/DI 141 5
1 individuals seeking licensure under sections 11(c)(3) and 12(b)(3)
2 of this chapter.
3 SECTION 6. IC 25-26-13-10, AS AMENDED BY P.L.143-2022,
4 SECTION 57, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
5 JULY 1, 2025]: Sec. 10. (a) An applicant for registration as a
6 pharmacist intern must furnish proof satisfactory to the board that the
7 applicant:
8 (1) is actively enrolled in a school of pharmacy accredited by the
9 American Accreditation Council for Pharmacy Education;
10 (2) has obtained the Foreign Pharmacy Graduate Examination
11 Committee Certificate; or
12 (3) is a qualified applicant awaiting the examination for licensure
13 as a pharmacist.
14 (b) A registration issued under subsection (a) is valid for one (1)
15 year and may be renewed by the board in accordance with subsection
16 (c) until the expiration date established by the Indiana professional
17 licensing agency under IC 25-1-5-4.
18 (c) An application for registration or renewal must be accompanied
19 by the appropriate fee and one (1) of the following:
20 (1) Proof of having obtained the Foreign Pharmacy Graduate
21 Examination Committee Certificate.
22 (2) Proof of active enrollment in a school of pharmacy accredited
23 by the American Accreditation Council for Pharmacy Education.
24 SECTION 7. IC 25-26-13-11, AS AMENDED BY P.L.143-2022,
25 SECTION 58, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
26 JULY 1, 2025]: Sec. 11. (a) To be eligible for licensure as a
27 pharmacist, an individual must file such evidence as is required by the
28 board that:
29 (1) the individual is at least eighteen (18) years of age;
30 (2) the individual does not have a conviction for a crime that has
31 a direct bearing on the individual's ability to practice competently;
32 (3) the individual:
33 (A) has graduated with a professional degree from a school of
34 pharmacy located in the United States or Canada that is
35 accredited by the American Accreditation Council for
36 Pharmacy Education or the Canadian Council for
37 Accreditation of Pharmacy Programs and approved by the
38 board; or
39 (B) has:
40 (i) graduated with a professional degree from a school of
41 pharmacy located outside the United States and Canada; and
42 (ii) met the requirements under subsection (c); and
2025	IN 1571—LS 7666/DI 141 6
1 (4) the individual has satisfactorily completed a pharmacist intern
2 program approved by the board;
3 (5) the individual has successfully passed the North American
4 Pharmacist Licensure Examination administered by the
5 National Association of Boards of Pharmacy; and
6 (6) if the individual graduated with a professional degree from
7 a school of pharmacy:
8 (A) accredited by the Accreditation Council for Pharmacy
9 Education; and
10 (B) located outside of Indiana, but within the United States
11 or Canada;
12 the individual has completed the initial course of education
13 described in section 9(c) of this chapter.
14 (b) An applicant who has graduated with a professional degree from
15 a school of pharmacy accredited by the Canadian Council for
16 Accreditation of Pharmacy Programs and approved by the board must
17 obtain the Foreign Pharmacy Graduate Examination Committee
18 Certificate administered by the National Association of Boards of
19 Pharmacy before taking the examination required under subsection (d).
20 (a)(5).
21 (c) An applicant who has graduated with a professional degree from
22 a school of pharmacy located outside the United States and Canada
23 must do the following:
24 (1) Provide the board with verification of the applicant's academic
25 record and graduation.
26 (2) Obtain the Foreign Pharmacy Graduate Examination
27 Committee Certificate administered by the National Association
28 of Boards of Pharmacy.
29 (3) Complete the initial course of education described in
30 section 9(c) and 9(d) of this chapter.
31 (d) After filing an application on a form provided by the board and
32 submitting the information required in subsection (a), and successfully
33 completing the examination administered by the board, the applicant
34 may be licensed as a pharmacist.
35 SECTION 8. IC 25-26-13-12, AS AMENDED BY P.L.143-2022,
36 SECTION 59, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
37 JULY 1, 2025]: Sec. 12. (a) An individual who is licensed as a
38 pharmacist in another state where the requirements for licensure were
39 not less than those required in this state at the time of original licensure
40 may be issued a license in this state if:
41 (1) the individual has registered with and been approved by the
42 National Association of Boards of Pharmacy;
2025	IN 1571—LS 7666/DI 141 7
1 (2) the individual has graduated with a professional degree in
2 pharmacy from a school of pharmacy accredited by the American
3 Accreditation Council for Pharmacy Education or the Canadian
4 Council for Accreditation of Pharmacy Programs and approved by
5 the board; and
6 (3) the individual has successfully completed an examination
7 administered by the board concerning the federal statutes and
8 regulations and the Indiana statutes and rules governing the
9 practice of pharmacy. the initial course of education described
10 in section 9(c) of this chapter.
11 (b) An individual who has a professional pharmacy degree from a
12 school of pharmacy located outside the United States and Canada and
13 who is licensed in another state where the requirements for licensure
14 are substantially the same as those in this state may be issued a license
15 under this chapter if:
16 (1) the individual has registered with and been approved by the
17 National Association of Boards of Pharmacy;
18 (2) the individual has provided the board with proof of the
19 applicant's:
20 (A) academic record and graduation with a professional degree
21 from a school of pharmacy; and
22 (B) completion of the requirements for obtaining a Foreign
23 Pharmacy Graduate Examination Committee Certificate
24 administered by the National Association of Boards of
25 Pharmacy; and
26 (3) the individual has successfully completed an examination
27 administered by the board concerning the federal statutes and
28 regulations and the Indiana statutes and rules governing the
29 practice of pharmacy. the initial course of education described
30 in section 9(c) and 9(d) of this chapter.
31 SECTION 9. IC 25-26-13-31.1 IS ADDED TO THE INDIANA
32 CODE AS A NEW SECTION TO READ AS FOLLOWS
33 [EFFECTIVE JULY 1, 2025]: Sec. 31.1. A pharmacist may treat
34 health conditions and order tests to guide the pharmacist's clinical
35 decision making under a standing order, prescription, or protocol
36 issued by the state health commissioner. However, the test must be:
37 (1) a waived test under the federal Clinical Laboratory
38 Improvement Amendments (CLIA), including a test system
39 cleared by the federal Food and Drug Administration for
40 home use or a test approved for waiver under the CLIA; or
41 (2) established under the standing order, prescription, or
42 protocol issued by the state health commissioner.
2025	IN 1571—LS 7666/DI 141 8
1 SECTION 10. IC 25-26-13-31.2, AS AMENDED BY P.L.56-2023,
2 SECTION 239, IS AMENDED TO READ AS FOLLOWS
3 [EFFECTIVE JULY 1, 2025]: Sec. 31.2. (a) A pharmacist may
4 administer an immunization to an individual under a drug order or
5 prescription.
6 (b) Subject to subsection (c), a pharmacist may administer or
7 dispense immunizations for the following an immunization that is
8 recommended by the federal Centers for Disease Control and
9 Prevention Advisory Committee on Immunization Practices to a
10 group of individuals under a drug order, under a prescription, or
11 according to a protocol approved by a physician.
12 (1) Influenza.
13 (2) Shingles (herpes zoster).
14 (3) Pneumonia.
15 (4) Tetanus, diphtheria, and acellular pertussis (whooping cough).
16 (5) Human papillomavirus (HPV) infection.
17 (6) Meningitis.
18 (7) Measles, mumps, and rubella.
19 (8) Varicella.
20 (9) Hepatitis A.
21 (10) Hepatitis B.
22 (11) Haemophilus influenzae type b (Hib).
23 (12) Coronavirus disease.
24 (c) A pharmacist may administer an immunization under subsection
25 (b) if the following requirements are met:
26 (1) The physician specifies in the drug order, prescription, or
27 protocol the group of individuals to whom the immunization may
28 be administered.
29 (2) The physician who writes the drug order, prescription, or
30 protocol is licensed and actively practicing with a medical office
31 in Indiana and not employed by a pharmacy.
32 (3) Subject to subsection (e), the pharmacist who administers the
33 immunization is responsible for notifying, reporting to the
34 immunization data registry (IC 16-38-5) not later than fourteen
35 (14) days after the pharmacist administers the immunization. the
36 physician who authorized the immunization and the individual's
37 primary care physician that the individual received the
38 immunization.
39 (4) If the physician uses a protocol, the protocol may apply only
40 to an individual or group of individuals who:
41 (A) except as provided in clause (B), are at least eleven (11)
42 years of age; or
2025	IN 1571—LS 7666/DI 141 9
1 (B) for the pneumonia immunization under subsection (b)(3),
2 are at least fifty (50) years of age.
3 (5) (4) Before administering an immunization to an individual
4 according to a protocol approved by a physician, the pharmacist
5 must receive the consent of one (1) of the following:
6 (A) If the individual to whom the immunization is to be
7 administered is at least eleven (11) years of age but less than
8 eighteen (18) years of age, the parent or legal guardian of the
9 individual.
10 (B) If the individual to whom the immunization is to be
11 administered is at least eighteen (18) years of age but has a
12 legal guardian, the legal guardian of the individual.
13 (C) If the individual to whom the immunization is to be
14 administered is at least eighteen (18) years of age but has no
15 legal guardian, the individual.
16 A parent or legal guardian who is required to give consent under
17 this subdivision must be present at the time of immunization.
18 (d) If the Indiana department of health or the department of
19 homeland security determines that an emergency exists, subject to
20 IC 16-41-9-1.7(a)(2), a pharmacist may administer any immunization
21 in accordance with:
22 (1) the requirements of subsection (c)(1) through (c)(3); and
23 (2) any instructions in the emergency determination.
24 (e) A pharmacist or pharmacist's designee shall provide
25 immunization data to the immunization data registry (IC 16-38-5) in a
26 manner prescribed by the Indiana department of health unless:
27 (1) the individual receiving the immunization;
28 (2) the parent of the individual receiving the immunization, if the
29 individual receiving the immunization is less than eighteen (18)
30 years of age; or
31 (3) the legal guardian of the individual receiving the
32 immunization, if a legal guardian has been appointed;
33 has completed and filed with the pharmacist or pharmacist's designee
34 a written immunization data exemption form, as provided in
35 IC 16-38-5-2.
36 (f) If an immunization is administered under a protocol, then the
37 name, license number, and contact information of the physician who
38 wrote the protocol must be posted in the location where the
39 immunization is administered. A copy of the protocol must be available
40 for inspection by the individual receiving the immunization.
41 (g) A pharmacist may administer an immunization that is provided
42 according to a standing order, prescription, or protocol issued under
2025	IN 1571—LS 7666/DI 141 10
1 this section or IC 16-19-4-11 by the state health commissioner. or the
2 commissioner's designated public health authority who is a licensed
3 prescriber. If a pharmacist has received a protocol to administer an
4 immunization from a physician and that specific immunization is
5 covered by a standing order, prescription, or protocol issued by the
6 state health commissioner, or the commissioner's designated public
7 health authority, the pharmacist must administer the immunization
8 according to the standing order, prescription, or protocol issued by the
9 state health commissioner. or the commissioner's designated public
10 health authority.
11 SECTION 11. IC 25-26-13-31.5, AS AMENDED BY P.L.207-2021,
12 SECTION 37, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
13 JULY 1, 2025]: Sec. 31.5. (a) Subject to rules adopted under
14 subsection (c), a pharmacist intern or a pharmacist student may
15 administer an immunization to an individual under a drug order or
16 prescription.
17 (b) Subject to rules adopted under subsection (c), a pharmacist
18 intern or a pharmacist student may administer an immunization to an
19 individual or a group of individuals under a drug order, under a
20 prescription, or according to a protocol approved by a physician.
21 (c) The board shall adopt rules under IC 4-22-2 to establish
22 requirements applying to a pharmacist intern or a pharmacist student
23 who administers an immunization to an individual or group of
24 individuals. The rules adopted under this section:
25 (1) must provide for the direct supervision of the pharmacist
26 intern or pharmacist student by a pharmacist, a physician, a
27 physician assistant, an advanced practice registered nurse, or a
28 registered nurse; and
29 (2) may not be less stringent than the requirements applying to a
30 pharmacist who administers an immunization to an individual as
31 provided under section 31.2 of this chapter.
32 (d) A pharmacist intern may perform a test that is:
33 (1) delegated by a supervising pharmacist; and
34 (2) a waived test under the federal Clinical Laboratory
35 Improvement Amendments (CLIA), including a test system
36 cleared by the federal Food and Drug Administration for
37 home use or a test approved for waiver under the CLIA.
38 SECTION 12. IC 25-26-13-31.7, AS AMENDED BY P.L.93-2024,
39 SECTION 188, IS AMENDED TO READ AS FOLLOWS
40 [EFFECTIVE JULY 1, 2025]: Sec. 31.7. (a) Subject to rules adopted
41 under subsection (c), a pharmacy technician may administer any
42 immunization to an individual under a drug order or prescription, as
2025	IN 1571—LS 7666/DI 141 11
1 delegated by the pharmacist.
2 (b) Subject to rules adopted under subsection (c), a pharmacy
3 technician may administer an immunization to an individual or a group
4 of individuals under a drug order, under a prescription, or according to
5 a protocol approved by a physician, as delegated by the pharmacist.
6 (c) The board shall adopt rules under IC 4-22-2 to establish
7 requirements applying to a pharmacy technician who administers an
8 immunization to an individual or group of individuals. The rules
9 adopted under this section must provide for the direct supervision of
10 the pharmacy technician by a pharmacist, a physician, a physician
11 assistant, or an advanced practice registered nurse.
12 (d) The board must approve all programs that provide training to
13 pharmacy technicians to administer immunizations as permitted by this
14 section.
15 (e) A pharmacy technician may perform a test that is:
16 (1) delegated by a supervising pharmacist; and
17 (2) a waived test under the federal Clinical Laboratory
18 Improvement Amendments (CLIA), including a test system
19 cleared by the federal Food and Drug Administration for
20 home use or a test approved for waiver under the CLIA.
21 SECTION 13. IC 25-26-13-35 IS ADDED TO THE INDIANA
22 CODE AS A NEW SECTION TO READ AS FOLLOWS
23 [EFFECTIVE JULY 1, 2025]: Sec. 35. (a) Nothing in this section
24 grants civil immunity to a pharmacist or pharmacy whose actions
25 or omissions, as proven by clear and convincing evidence,
26 constitute gross negligence or willful or wanton misconduct,
27 including fraud and intentional acts.
28 (b) For purposes of this section, the absence of a diagnosis or a
29 diagnosis code on the prescription by the prescriber indicating that
30 the drug, medicine, or other prescribed substance is intended for
31 a purpose other than to cause an abortion does not constitute
32 actual knowledge.
33 (c) Unless a pharmacist or pharmacy has actual knowledge that
34 a prescription is intended for the purpose of causing an abortion,
35 a pharmacist or pharmacy is not subject to a criminal action
36 related to filling a prescription for a drug, medicine, or other
37 prescribed substance.
38 (d) Unless a pharmacist or pharmacy has actual knowledge that
39 a prescription is intended for the purpose of causing an abortion,
40 a pharmacist or pharmacy is immune from civil liability for
41 damages arising from filling a prescription for a drug, medicine, or
42 other prescribed substance.
2025	IN 1571—LS 7666/DI 141 12
1 SECTION 14. IC 25-26-13.5-9, AS AMENDED BY P.L.143-2022,
2 SECTION 68, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3 JULY 1, 2025]: Sec. 9. (a) There must be at least one (1) pharmacist
4 working at a remote dispensing facility for every six (6) pharmacist
5 interns, licensed pharmacy technicians, and pharmacy technicians in
6 training at the supervising pharmacy and remote dispensing facility.
7 However, an individual whose only duty is to act as the cashier is not
8 included in the number of employees that may work for one (1)
9 pharmacist under this subsection.
10 (b) A remote dispensing facility that is not staffed by a pharmacist
11 must be staffed by at least one (1) pharmacy technician who meets the
12 following requirements:
13 (1) Is licensed under IC 25-26-19.
14 (2) Has at least two thousand (2,000) hours of experience working
15 as a pharmacy technician in a pharmacy licensed under this article
16 and under the direct supervision of a pharmacist.
17 (3) Has successfully passed a certification examination offered by
18 the Pharmacy Technician Certification Board or another
19 nationally recognized certification body approved by the board.
20 (4) If the remote dispensing facility is located in a hospital or
21 physician clinic setting, either:
22 (A) has graduated from a pharmacy technician training
23 program accredited by the American Accreditation Council
24 for Pharmacy Education or the American Society of Health
25 System Pharmacists; or
26 (B) obtained the hours described in subdivision (2) before July
27 1, 2017.
28 (5) Is supervised by a pharmacist at the supervising pharmacy at
29 all times that the remote dispensing facility is operational. As
30 used in this subdivision, supervision does not require that the
31 pharmacist be physically present at the remote dispensing facility
32 as long as the pharmacist is supervising telepharmacy operations
33 electronically through a computer link, video link, and audio link.
34 (6) Is currently in good standing with the board.
35 (c) A pharmacy technician in training may not work at a remote
36 dispensing facility unless a pharmacist is on site.
37 (d) The board shall adopt rules that require pharmacy technicians
38 working at a remote dispensing facility that is not staffed by a
39 pharmacist to complete continuing education requirements established
40 by the board.
41 SECTION 15. IC 25-26-19-8, AS AMENDED BY P.L.58-2014,
42 SECTION 15, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
2025	IN 1571—LS 7666/DI 141 13
1 JULY 1, 2025]: Sec. 8. (a) A licensed pharmacy technician may not
2 perform the following activities:
3 (1) Providing advice or consultation with the prescribing
4 practitioner or other licensed health care provider regarding the
5 patient or the interpretation and application of information
6 contained in the prescription or drug order, medical record, or
7 patient profile.
8 (2) Providing advice or consultation with the patient regarding the
9 interpretation of the prescription or the application of information
10 contained in the patient profile or medical record.
11 (3) Dispensing prescription drug information to the patient.
12 (4) Final check on all aspects of the completed prescription and
13 assumption of the responsibility for the filled prescription,
14 including the appropriateness of the drug for the patient and the
15 accuracy of the:
16 (A) drug dispensed;
17 (B) strength of the drug dispensed; and
18 (C) labeling of the prescription.
19 (5) Receiving a new prescription drug order over the telephone or
20 electronically unless the original information is recorded so a
21 pharmacist may review the prescription drug order as transmitted.
22 (6) Any activity required by law to be performed only by a
23 pharmacist.
24 (7) Any activity that requires the clinical judgment of a
25 pharmacist and is prohibited by a rule adopted by the board.
26 (b) Notwithstanding subsection (a), a licensed pharmacy
27 technician, who holds an active certification from the Pharmacy
28 Technician Certification Board or other nationally recognized
29 certification approved by the board, may perform any activity
30 delegated by a supervising pharmacist, including those activities
31 described in subsection (a)(4) and (a)(5), if the activities:
32 (1) do not require the clinical judgment of a pharmacist;
33 (2) are not prohibited by a rule adopted by the board; or
34 (3) are not activities required by law to be performed only by
35 a pharmacist.
36 (c) A licensed pharmacy technician who performs the activities
37 permitted under subsection (b) must be properly trained and
38 competent to perform the delegated activity. The pharmacy must
39 keep a record of the licensed pharmacy technician's training and
40 documentation to support the licensed pharmacy technician's
41 competency.
42 (d) A person or corporate entity may not mandate a protocol or
2025	IN 1571—LS 7666/DI 141 14
1 procedure that interferes with a pharmacist's ability to exercise the
2 pharmacist's independent professional judgment under this
3 section, including whether to allow a licensed pharmacy technician
4 to conduct the activities described in subsection (a)(4) and (a)(5).
5 SECTION 16. IC 25-26-27 IS ADDED TO THE INDIANA CODE
6 AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
7 JULY 1, 2025]:
8 Chapter 27. Medication Assisted Treatment
9 Sec. 1. The definitions in IC 25-26-13-2 apply throughout this
10 chapter.
11 Sec. 2. As used in this chapter, "medication assisted treatment"
12 means treatment for a substance use disorder using medication,
13 including controlled substances, that is:
14 (1) approved by the federal Food and Drug Administration
15 for the treatment of a substance use disorder; and
16 (2) prescribed, dispensed, or administered in accordance with
17 national, evidence based published guidance.
18 Sec. 3. To the extent authorized by federal law, a pharmacist
19 may, in accordance with rules adopted by the board:
20 (1) assess a patient to determine whether:
21 (A) the patient has a substance use disorder; and
22 (B) medication assisted treatment would be appropriate
23 for the patient;
24 (2) counsel and provide information to the patient concerning
25 evidence based treatment for substance use disorders,
26 including medication assisted treatment;
27 (3) prescribe and dispense a drug, including a controlled
28 substance, for medication assisted treatment; and
29 (4) prescribe and dispense a drug for the treatment of
30 withdrawal in accordance with national, evidence based
31 published guidance on outpatient withdrawal management.
32 Sec. 4. Not later than October 1, 2026, the board shall adopt
33 rules under IC 4-22-2 establishing a statewide drug therapy
34 protocol for the actions authorized under this chapter.
35 SECTION 17. IC 27-1-24.5-1.3 IS ADDED TO THE INDIANA
36 CODE AS A NEW SECTION TO READ AS FOLLOWS
37 [EFFECTIVE JULY 1, 2025]: Sec. 1.3. (a) As used in this chapter,
38 "discount card" means a card, purchasing mechanism, or device,
39 that:
40 (1) is not insurance; and
41 (2) purports to offer discounts or access to discounts for retail
42 purchases of prescription drugs from licensed pharmacies.
2025	IN 1571—LS 7666/DI 141 15
1 (b) The term does not include the following:
2 (1) A health plan provided by a self-insured employer.
3 (2) A state employee health plan (as defined in IC 5-10-8-6.7).
4 (3) A policy of accident and sickness insurance (as defined in
5 IC 27-8-5-1).
6 (4) An individual contract (as defined in IC 27-13-1-21) or a
7 group contract (as defined in IC 27-13-1-16) that provides
8 coverage for basic health care services (as defined in
9 IC 27-13-1-4).
10 SECTION 18. IC 27-1-24.5-2, AS ADDED BY P.L.68-2020,
11 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
12 JULY 1, 2025]: Sec. 2. As used in this chapter, "effective rate of
13 reimbursement" includes the following:
14 (1) Generic effective rates.
15 (2) Brand effective rates.
16 (3) Direct and indirect remuneration fees.
17 (4) Any other reduction or aggregate reduction of payment,
18 including any failure to pay the total reimbursement rate
19 within twenty-one (21) days after the provision of pharmacy
20 or pharmacist services.
21 SECTION 19. IC 27-1-24.5-3, AS ADDED BY P.L.68-2020,
22 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
23 JULY 1, 2025]: Sec. 3. As used in this chapter, "equal access and
24 incentives" means that a pharmacy benefit manager allows any willing
25 pharmacy provider to participate, as part of any of the pharmacy benefit
26 manager's networks through an agreement or health plan contract,
27 to provide pharmacy or pharmacist services as long as the pharmacy
28 provider agrees to the terms and conditions of the relevant contract.
29 applicable to any other pharmacy provider within that network.
30 SECTION 20. IC 27-1-24.5-12, AS AMENDED BY P.L.32-2021,
31 SECTION 77, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
32 JULY 1, 2025]: Sec. 12. (a) As used in this chapter, "pharmacy benefit
33 manager" means an entity that, on behalf of a health plan, state agency,
34 insurer, managed care organization, or other third party payor:
35 (1) contracts directly or indirectly with pharmacies to provide
36 prescription drugs to individuals;
37 (2) administers a prescription drug benefit;
38 (3) processes or pays pharmacy claims;
39 (4) creates or updates prescription drug formularies;
40 (5) makes or assists in making prior authorization determinations
41 on prescription drugs;
42 (6) administers rebates on prescription drugs; or
2025	IN 1571—LS 7666/DI 141 16
1 (7) establishes a pharmacy network. health plan contract to
2 provide pharmacy or pharmacist services.
3 (b) The term does not include the following:
4 (1) A person licensed under IC 16.
5 (2) A health provider who is:
6 (A) described in IC 25-0.5-1; and
7 (B) licensed or registered under IC 25.
8 (3) A consultant who only provides advice concerning the
9 selection or performance of a pharmacy benefit manager.
10 SECTION 21. IC 27-1-24.5-14, AS ADDED BY P.L.68-2020,
11 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
12 JULY 1, 2025]: Sec. 14. As used in this chapter, "pharmacy benefit
13 manager network" provider" means a group of any pharmacies or
14 pharmacists that is are offered:
15 (1) through an agreement or health plan contract; and
16 (2) to provide pharmacy or pharmacist services for health plans.
17 SECTION 22. IC 27-1-24.5-16.5 IS ADDED TO THE INDIANA
18 CODE AS A NEW SECTION TO READ AS FOLLOWS
19 [EFFECTIVE JULY 1, 2025]: Sec. 16.5. As used in this chapter,
20 "specialty drug" means a subset of prescription drugs that meet
21 three (3) or more of the following criteria:
22 (1) Require special handling or storage.
23 (2) Require complex and extended education or counseling of
24 a covered individual.
25 (3) Require intensive monitoring.
26 (4) Require clinical oversight.
27 (5) Require product support services for drugs that are used
28 to treat chronic and complex or rare medical conditions that
29 can be:
30 (A) progressive; or
31 (B) debilitating or fatal if left untreated or undertreated.
32 SECTION 23. IC 27-1-24.5-19, AS AMENDED BY P.L.196-2021,
33 SECTION 22, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
34 JULY 1, 2025]: Sec. 19. (a) A pharmacy benefit manager shall provide
35 the following:
36 (1) Equal access and incentives to all pharmacies within the
37 pharmacy benefit manager's network. pharmacy providers.
38 (2) A pharmacy provider that is not a mail order or Internet
39 based pharmacy (as defined in IC 25-26-18-1) not more than
40 thirty (30) miles from each covered individual's residence to
41 the extent that pharmacy or pharmacist services are
42 available.
2025	IN 1571—LS 7666/DI 141 17
1 (b) A pharmacy benefit manager may not do any of the following:
2 (1) Condition pharmacy provider participation in any network
3 on accreditation, credentialing, or licensing of a pharmacy, other
4 than a license or permit required by the Indiana board of
5 pharmacy or other state or federal regulatory authority for the
6 services provided by the pharmacy. However, nothing in this
7 subdivision precludes the department from providing
8 credentialing or accreditation standards for pharmacies.
9 (2) Discriminate against any pharmacy.
10 (3) Directly or indirectly retroactively deny a claim or aggregate
11 of claims after the claim or aggregate of claims has been
12 adjudicated, unless any of the following apply:
13 (A) The original claim was submitted fraudulently.
14 (B) The original claim payment was incorrect because the
15 pharmacy or pharmacist had already been paid for the drug.
16 (C) The pharmacy or pharmacist services were not properly
17 rendered by the pharmacy or pharmacist.
18 (4) Reduce, directly or indirectly, payment to a pharmacy for
19 pharmacist services to an effective rate of reimbursement,
20 including permitting an insurer or plan sponsor to make such a
21 reduction.
22 (5) Reimburse a pharmacy that is affiliated with the pharmacy
23 benefit manager affiliate other than solely being included in the
24 pharmacy benefit manager's network, at a greater reimbursement
25 rate than other pharmacies in the same network. pharmacy
26 providers.
27 (6) Impose limits, including quantity limits or refill frequency
28 limits, on a pharmacy's access to medication that differ from those
29 existing for a pharmacy benefit manager affiliate.
30 (7) Share any covered individual's information, including
31 de-identified covered individual information, received from a
32 pharmacy or pharmacy benefit manager affiliate, except as
33 permitted by the federal Health Insurance Portability and
34 Accountability Act (HIPAA) (P.L.104-191).
35 (8) Prohibit or limit any covered individual from selecting a
36 pharmacy or pharmacist who has agreed to participate in the
37 health plan according to the terms offered by the health plan.
38 (9) Contract solely with a pharmacy benefit manager affiliate.
39 (10) Impose on a covered individual of pharmacy or
40 pharmacist services any copayment, fee, or condition that is
41 not equally imposed on all covered individuals.
42 (11) Impose a monetary advantage or penalty under a health
2025	IN 1571—LS 7666/DI 141 18
1 plan that would affect a covered individual's choice among the
2 pharmacies or pharmacists who have agreed to participate in
3 the health plan according to the terms offered by the health
4 plan. For purposes of this subdivision, monetary advantage or
5 penalty includes any of the following:
6 (A) Higher copayment.
7 (B) A reduction in reimbursement for services.
8 (C) Promotion of one (1) participating pharmacy over
9 another by using the methods listed in clause (A) or (B).
10 (12) Prohibit or otherwise limit a beneficiary's access to
11 prescription drugs from a pharmacy or pharmacist enrolled
12 with the health plan under the terms offered to all pharmacies
13 in the health plan coverage area by unreasonably designating
14 a covered prescription drug as a specialty drug.
15 (13) Limit a covered individual's access to specialty drugs,
16 including by designating a drug as a specialty drug based
17 solely on cost.
18 (14) Reimburse a pharmacy provider for a prescription drug
19 or pharmacy or pharmacist service in an amount less than the
20 amount determined in STEP THREE of the following
21 formula:
22 STEP ONE: Determine the national average drug
23 acquisition cost for the prescription drug or pharmacy or
24 pharmacist service at the time the drug is administered or
25 dispensed
26 STEP TWO: Determine a professional dispensing fee equal
27 to the Medicaid fee-for-service dispensing fee under 405
28 IAC 5-24-6. If a pharmacy provider is located in a rural
29 health area as defined by the United States Health
30 Resources and Services Administration, add three dollars
31 ($3) to this amount.
32 STEP THREE: Add the amount determined under STEP
33 ONE to the amount determined under STEP TWO.
34 If the national average drug acquisition cost is not available
35 at the time a drug is administered or dispensed, a pharmacy
36 benefit manager may not reimburse in an amount that is less
37 than the wholesale acquisition cost of the drug at the time the
38 drug is administered or dispensed plus a professional
39 dispensing fee equal to the Medicaid fee-for-service dispensing
40 fee under 405 IAC 5-24-6.
41 (15) Charge a fee, require an inspection, or invoke a waiting
42 period to a pharmacy provider for credentialing.
2025	IN 1571—LS 7666/DI 141 19
1 (16) Institute aberrant quantity and volume provisions as a
2 requirement for pharmacy provider inclusion.
3 (17) Prohibit a pharmacy or pharmacist from:
4 (A) refusing to fill; or
5 (B) communicating to the covered individual the reason for
6 refusal to fill;
7 a prescription based on the pharmacy or pharmacist's
8 reimbursement.
9 (18) Apply, without a pharmacy provider's consent, a discount
10 card for coverage of prescription drugs, unless a health plan
11 or pharmacy benefit manager that uses a discount card:
12 (A) clearly describes the nature of the use in any contract
13 with a pharmacy, pharmacy provider, pharmacy services
14 administrative organization, and all other health plans;
15 (B) ensures that no retroactive or post-claim adjudication,
16 fee, or any other financial cost regardless of name is
17 charged to a pharmacy provider for use of a discount card;
18 and
19 (C) ensures that the pharmacy provider is reimbursed at
20 a rate that complies with subdivision (14) after a discount
21 card is applied.
22 A violation of this subsection by a pharmacy benefit manager
23 constitutes an unfair or deceptive act or practice in the business of
24 insurance under IC 27-4-1-4.
25 SECTION 24. IC 27-1-24.5-21, AS ADDED BY P.L.68-2020,
26 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
27 JULY 1, 2025]: Sec. 21. (a) Beginning June 1, 2021, and annually
28 thereafter, a pharmacy benefit manager shall submit a report containing
29 data from the immediately preceding calendar year to the
30 commissioner. The commissioner shall determine what must be
31 included in the report and consider the following information to be
32 included in the report:
33 (1) The aggregate amount of all rebates that the pharmacy benefit
34 manager received from all pharmaceutical manufacturers for:
35 (A) all insurers; and
36 (B) each insurer;
37 with which the pharmacy benefit manager contracted during the
38 immediately preceding calendar year.
39 (2) The aggregate amount of administrative fees that the
40 pharmacy benefit manager received from all pharmaceutical
41 manufacturers for:
42 (A) all insurers; and
2025	IN 1571—LS 7666/DI 141 20
1 (B) each insurer;
2 with which the pharmacy benefit manager contracted during the
3 immediately preceding calendar year.
4 (3) The aggregate amount of retained rebates that the pharmacy
5 benefit manager received from all pharmaceutical manufacturers
6 and did not pass through to insurers with which the pharmacy
7 benefit manager contracted during the immediately preceding
8 calendar year.
9 (4) The highest, lowest, and mean aggregate retained rebate for:
10 (A) all insurers; and
11 (B) each insurer;
12 with which the pharmacy benefit manager contracted during the
13 immediately preceding calendar year.
14 (5) An adequacy report describing the pharmacy providers
15 and covered individuals' access to pharmacy providers in
16 Indiana.
17 (6) Any and all pharmacy benefit manager affiliates in
18 Indiana.
19 (b) A pharmacy benefit manager that provides information under
20 this section may designate the information as a trade secret (as defined
21 in IC 24-2-3-2). Information designated as a trade secret under this
22 subsection must not be published unless required under subsection (c).
23 (c) Disclosure of information designated as a trade secret under
24 subsection (b) may be ordered by a court of Indiana for good cause
25 shown or made in a court filing.
26 SECTION 25. IC 27-1-24.5-22, AS AMENDED BY P.L.196-2021,
27 SECTION 24, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
28 JULY 1, 2025]: Sec. 22. (a) A pharmacy benefit manager shall do the
29 following:
30 (1) Identify to contracted:
31 (A) pharmacy services administrative organizations; or
32 (B) pharmacies if the pharmacy benefit manager contracts
33 directly with pharmacies;
34 the sources used by the pharmacy benefit manager to calculate the
35 drug product reimbursement paid for covered drugs available
36 under the pharmacy health plan administered by the pharmacy
37 benefit manager.
38 (2) Establish an appeal process for contracted pharmacies,
39 pharmacy services administrative organizations, or group
40 purchasing organizations to appeal and resolve disputes
41 concerning the maximum allowable cost pricing.
42 (3) Update and make available to pharmacies:
2025	IN 1571—LS 7666/DI 141 21
1 (A) at least every seven (7) days; or
2 (B) in a different time frame if contracted between a pharmacy
3 benefit manager and a pharmacy;
4 the pharmacy benefit manager's maximum allowable cost list.
5 (4) Determine that a prescription drug:
6 (A) is not obsolete;
7 (B) is generally available for purchase by pharmacies in
8 Indiana from a national or regional wholesaler licensed in
9 Indiana; and
10 (C) is not:
11 (i) temporarily unavailable;
12 (ii) listed on a drug shortage list; or
13 (iii) unable to be lawfully substituted;
14 before the prescription drug is placed or continued on a maximum
15 allowable cost list.
16 (b) The appeal process required by subsection (a)(2) must include
17 the following:
18 (1) The right to appeal a claim not to exceed sixty (60) days
19 following the initial filing of the claim.
20 (2) The investigation and resolution of a filed appeal by the
21 pharmacy benefit manager in a time frame determined by the
22 commissioner.
23 (3) If an appeal is denied, a requirement that the pharmacy benefit
24 manager do the following:
25 (A) Provide the reason for the denial.
26 (B) Provide the appealing contracted pharmacy, pharmacy
27 services administrative organization, or group purchasing
28 organization with the national drug code number of the
29 prescription drug that is available from a national or regional
30 wholesaler operating in Indiana to be purchased by the
31 contracted pharmacy, pharmacy services administrative
32 organization, or group purchasing organization at the
33 listed maximum allowable cost.
34 (4) If an appeal is approved, a requirement that the pharmacy
35 benefit manager do the following:
36 (A) Change the maximum allowable cost of the drug for the
37 pharmacy that filed the appeal as of the initial date of service
38 that the appealed drug was dispensed.
39 (B) Adjust the maximum allowable cost of the drug for the
40 appealing pharmacy and for all other contracted pharmacies in
41 the same network of the pharmacy benefit manager that filled
42 a prescription for patients covered under the same health plan
2025	IN 1571—LS 7666/DI 141 22
1 beginning on the initial date of service the appealed drug was
2 dispensed.
3 (C) Notify each pharmacy in the pharmacy benefit manager's
4 network that the maximum allowable cost for the drug has
5 been adjusted as a result of an approved appeal.
6 (D) Adjust the drug product reimbursement for contracted
7 pharmacies that resubmit claims to reflect the adjusted
8 maximum allowable cost, if applicable.
9 (E) Allow the appealing pharmacy and all other contracted
10 pharmacies in the network that filled the prescriptions for
11 patients covered under the same health plan to reverse and
12 resubmit claims and receive payment based on the adjusted
13 maximum allowable cost from the initial date of service the
14 appealed drug was dispensed.
15 (F) Make retroactive price adjustments in the next payment
16 cycle unless otherwise agreed to by the pharmacy.
17 (5) The establishment of procedures for auditing submitted claims
18 by a contracted pharmacy in a manner established by
19 administrative rules under IC 4-22-2 by the department. The
20 auditing procedures:
21 (A) may not use extrapolation or any similar methodology;
22 (B) may not allow for recovery by a pharmacy benefit manager
23 of a submitted claim due to clerical or other error where the
24 patient has received the drug for which the claim was
25 submitted;
26 (C) must allow for recovery by a contracted pharmacy for
27 underpayments by the pharmacy benefit manager; and
28 (D) may only allow for the pharmacy benefit manager to
29 recover overpayments on claims that are actually audited and
30 discovered to include a recoverable error.
31 (c) The department must approve the manner in which a pharmacy
32 benefit manager may respond to an appeal filed under this section. The
33 department shall establish a process for a pharmacy benefit manager to
34 obtain approval from the department under this section.
35 SECTION 26. IC 27-2-9.5 IS ADDED TO THE INDIANA CODE
36 AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
37 JULY 1, 2025]:
38 Chapter 9.5. Reimbursement for Pharmacist Services
39 Sec. 1. This chapter applies to a policy or contract that is
40 delivered, issued, or renewed after June 30, 2025.
41 Sec. 2. As used in this chapter, "health carrier" has the meaning
42 set forth in IC 27-1-46-3.
2025	IN 1571—LS 7666/DI 141 23
1 Sec. 3. As used in this chapter, "medication assisted treatment"
2 has the meaning set forth in IC 25-26-27-2.
3 Sec. 4. A health carrier may not deny reimbursement for
4 services and procedures that are performed by a pharmacist and
5 that are within the scope of the pharmacist's license if the same
6 services and procedures would be covered if performed by a
7 physician, an advanced practice registered nurse, or a physician
8 assistant.
9 Sec. 5. (a) A health carrier that provides coverage for treatment
10 of substance use disorders shall reimburse a licensed pharmacist
11 acting:
12 (1) within the licensed pharmacist's scope of practice; and
13 (2) in accordance with IC 25-26-27;
14 for the provision of medication assisted treatment services if the
15 health carrier provides coverage under the individual contract or
16 group contract for the same services provided by another licensed
17 health care provider.
18 (b) A health carrier shall reimburse a pharmacist under
19 subsection (a) at the same rate that the health carrier reimburses
20 another licensed health care provider in the health carrier's
21 network of participating providers for the same services.
22 SECTION 27. IC 34-30-2.1-197, AS ADDED BY P.L.105-2022,
23 SECTION 12, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
24 JULY 1, 2025]: Sec. 197. IC 16-19-4-11 (Concerning issuance of
25 certain standing orders, prescriptions, or protocols by the state health
26 commissioner). and designated public health authorities).
27 SECTION 28. IC 34-30-2.1-380.3 IS ADDED TO THE INDIANA
28 CODE AS A NEW SECTION TO READ AS FOLLOWS
29 [EFFECTIVE JULY 1, 2025]: Sec. 380.3. IC 25-26-13-35
30 (Concerning filling a prescription).
31 SECTION 29. IC 35-48-1-24 IS AMENDED TO READ AS
32 FOLLOWS [EFFECTIVE JULY 1, 2025]: Sec. 24. "Practitioner"
33 means a physician, dentist, veterinarian, scientific investigator,
34 pharmacy, pharmacist, hospital, or other institution or individual
35 licensed, registered, or otherwise permitted to distribute, dispense,
36 conduct research with respect to, or administer a controlled substance
37 in the course of professional practice or research in Indiana.
38 SECTION 30. [EFFECTIVE JULY 1, 2025] (a) 856 IAC 1-3.1-1 is
39 void. The publisher of the Indiana Administrative Code and the
40 Indiana Register shall remove this section from the Indiana
41 Administrative Code.
42 (b) This SECTION expires July 1, 2027.
2025	IN 1571—LS 7666/DI 141 24
1 SECTION 31. [EFFECTIVE JULY 1, 2025] (a) The Indiana board
2 of pharmacy shall amend 856 IAC 1-4-1 to conform to
3 IC 25-26-13-12, as amended by this act.
4 (b) This SECTION expires July 1, 2027.
2025	IN 1571—LS 7666/DI 141